Company intelligence / Profile preview

ReVision Optics

Lake Forest, California, United Statesois.net ↗

Ownership: Private
Development stage: Commercial

Overview

The company's lead product was the PresbyLens® corneal inlay for presbyopia. It received CE mark and was approved for sale in Europe. In the US, it underwent clinical trials involving 400 patients over two years to evaluate its efficacy and safety for near vision restoration due to presbyopia. The device was investigational and not FDA-approved at that time. The company has since ceased operations.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Raindrop Near Vision Inlay

Commercial

Indications: presbyopia

Partnerships

ProQuest InvestmentsDomain AssociatesCanaan PartnersInterWest Partners

Beyond the preview

Go deeper on ReVision Optics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReVision Optics.

Explore the full profile